Multilayer Microfluidic Device for Rapid SARS-CoV-2 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for SARS-CoV-2 infection, such as real-time RT-PCR, are expensive, time-consuming, and require specialized training and equipment, making them unsuitable for rapid and widespread detection, especially given the challenge of asymptomatic carriers and the need for monitoring the virus's presence, past infection, and spread.
Innovation Solution
A multilayer microfluidic device using ELISA principles for rapid detection of SARS-CoV-2 antigens, antibodies, and inflammatory markers, which is affordable, easy to use, and does not require specialized equipment, allowing for singleplex and multiplex detection of present or past infections in various bodily fluids without sample pretreatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If real-time RT-PCR is used for SARS-CoV-2 detection, then detection accuracy is improved, but detection time increases and device complexity increases
Solution Approach 1:
The patent replaces the complex molecular biology system (RT-PCR requiring thermal cycling, enzymes, and multiple reagents) with a simpler immunological system (lateral flow assay using antibody-antigen binding). This substitution maintains detection accuracy through specific antibody binding while dramatically reducing detection time to under 15 minutes and eliminating the need for specialized thermal cycler equipment.
Solution Approach 2:
The patent employs a disposable lateral flow test strip that integrates all necessary components (nitrocellulose membrane, conjugate pad, sample pad, and control lines) into a single-use device. This disposable approach eliminates the need for expensive, complex instrumentation while providing rapid results, making the test suitable for widespread deployment without specialized laboratories.
2Measurement precision
If real-time RT-PCR is used for SARS-CoV-2 detection, then detection accuracy is improved, but device complexity and training requirements increase
Solution Approach 1:
The patent replaces the complex molecular biology system (RT-PCR requiring thermal cycling, enzymes, and multiple reagents) with a simpler immunological system (lateral flow assay using antibody-antigen binding). This substitution maintains detection accuracy through specific antibody binding while dramatically reducing detection time to under 15 minutes and eliminating the need for specialized thermal cycler equipment.
Solution Approach 2:
The lateral flow assay is designed to be self-contained and self-explanatory, with visual result interpretation through colored lines that require no specialized training. The device performs all necessary functions automatically through capillary action, eliminating the need for complex instrumentation or trained personnel to operate sophisticated equipment.
3Measurement precision
If conventional ELISA is used for biomolecule detection, then detection sensitivity is improved, but detection time and operational complexity increase
Solution Approach 1:
The patent segments the conventional ELISA process into a compact lateral flow format, separating the sample application, conjugate binding, and detection zones along the test strip. This segmentation allows simultaneous occurrence of multiple reaction steps as the sample flows through the strip, reducing the total detection time from hours to under 15 minutes while maintaining sensitivity through preserved antibody-antigen binding chemistry.
Solution Approach 2:
The patent pre-coats the nitrocellulose membrane with capture antibodies and pre-conjugates detection antibodies with gold nanoparticles before device assembly. These preliminary actions eliminate the need for time-consuming incubation and washing steps required in conventional ELISA, enabling rapid detection while maintaining sensitivity through pre-optimized binding conditions.
4Reliability
If widespread testing is implemented to identify asymptomatic carriers, then pandemic monitoring is improved, but testing cost and operational complexity increase
Solution Approach 1:
The lateral flow assay is designed to be self-contained and self-explanatory, with visual result interpretation through colored lines that require no specialized training. The device performs all necessary functions automatically through capillary action, eliminating the need for complex instrumentation or trained personnel to operate sophisticated equipment.
Solution Approach 2:
The patent employs a disposable lateral flow test strip that integrates all necessary components (nitrocellulose membrane, conjugate pad, sample pad, and control lines) into a single-use device. This disposable approach eliminates the need for expensive, complex instrumentation while providing rapid results, making the test suitable for widespread deployment without specialized laboratories.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device enables rapid, reliable, and sensitive detection of SARS-CoV-2 biomarkers in under 10 minutes, suitable for point-of-care use by non-trained personnel, with minimal cross-reactivity and interference from other pathogens or endogenous substances, and can detect low concentrations of analytes in small sample volumes.
Implementation Method 1
an analyte in the sample application zone binds to the conjugation reagent in the conjugation reagent zone to form an analyte-conjugation reagent complex
Implementation Method 2
the analyte-conjugation reagent complex binds to the capture reagent in the capture zone to form a detectable signal in the capture zone
Implementation Method 3
the sample application layer, the conjugation layer, the capture layer, and the absorbent layer each comprise porous media
Data Source
AI summary
Multilayer diagnostic microfluidic devices for the capture of a present or past SARS-CoV-2 infection and/or COVID-19 disease from a fluid sample using a multiplexed ELISA-based assay and their methods of use are described herein. The devices comprise a sample application layer comprising a sample application zone: a conjugation layer comprising a conjugation reagent in a conjugation zone, wherein the conjugation reagent comprises a detectable marker; a capture layer comprising a capture reagent in a capture zone; and an absorbent layer. The layers above tire capture layer are removable to expose a detectable signal in the capture zone. Detectable analytes include a SARS-CoV-2 protein or an antigenic fragment thereof, an IgM, IgG, or IgA antibody associated with a SARS-CoV-2 infection and or COVID-19 disease, or an inflammatory biomarker associated with a SARS-CoV-2 infection and/or COVID-19 disease.